



Esito valutazione titoli per l'ammissione al Dottorato di ricerca in:

MEDICINA SPERIMENTALE (XXXIV ciclo)

AVVISO IMPORTANTE: visto l'elevato numero di candidati, i colloqui con i candidati inizieranno il giorno 6 settembre 2018 alle ore 9.00 invece che il 7 settembre come indicato nel bando.

IMPORTANT NOTICE: due to the great number of candidates, the interviews of the candidates will start on September 6th at 9.00 am instead of September 7th as stated in the call for application.

Nome	Cognome	Punteggio progetto	Punteggio curriculum	Punteggio totale	Esito (ammesso/non ammesso/ escluso*)	Data, orario e luogo di svolgimento del colloquio e titolo del progetto presentato
6 settembre 2018, ore 9.00 LITA Segrate, Via Fratelli Cervi 93 – 20090 Segrate						
ELEONORA	ADAMO	7	11	18	AMMESSA	IDENTIFICATION OF NEW TRANS-ACTING FACTORS IN A COHORT OF BECKWITH-WIEDEMANN SYNDROME (BWS) PATIENTS WITH MULTILOCUS IMPRINTING DISTURBANCES (MLID) THROUGH MULTIPLE GENOMIC APPROACHES
PASQUALE	AGOSTI	4	18	22	NON AMMESSO (punteggio insufficiente progetto)	---
RAMONA	BASON	9	12,5	21,5	AMMESSA	EPIGENETIC CHARACTERIZATION OF TUMOR INFILTRATING CD4+ T REGULATORY CELLS FOR THE IDENTIFICATION OF NOVEL ANTI-CANCER TARGETS
ALESSIA	BIBI	8	12	20	AMMESSA	DISSECTING GENE REGULATORY NETWORKS OF TUMOUR-INFILTRATING REGULATORY T LYMPHOCYTES THROUGH CROP-SEQ APPROACH
CLARISSA	BUTTI	9	11	20	AMMESSA	CHARACTERIZATION OF THE CDKL5 DEFICIENCY DISORDER IN MOUSE MODELS AND IDENTIFICATION OF PATHOLOGICAL BIOMARKERS THROUGH DIFFERENT MRI/MRS TECHNIQUES

MICHELA	CALVI	9	14	23	AMMESSA	PHENOTYPIC AND MOLECULAR CHARACTERIZATION OF INNATE LYMPHOID CELLS (ILCS) IN MYELODYSPLASTIC SYNDROMES (MDS): TOWARDS THE COMPREHENSION OF THEIR ROLE IN DISEASE ETIOLOGY AND PROGNOSIS
CLARA MARIA	CAMBRIA	7	12	19	AMMESSA	EVALUATION OF BUMETANIDE ACTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE
MARCO	CAPECCHI	4	20	24	NON AMMESSO (punteggio insufficiente progetto)	---
SARA	CARLI	7	14	21	AMMESSA	EXPLOITING COMPUTATIONAL BIOLOGY FOR TARGET IDENTIFICATION AND DRUG REPOSITIONING IN MECP2 DISORDERS
SARA	CASATI	7	15	22	AMMESSA	LIPIDOMICS OF PLATELET-RICH PLASMA: MASS SPECTROMETRY CHARACTERIZATION AND LIPID SIGNALING EVALUATION IN TISSUE REGENERATION
MARIA NICOL	COLOMBO	8	15	23	AMMESSA	ROLE OF THE VAPB GENE IN THE PATHOGENESIS OF ALS
SONIA	DE ROSE	6	9,5	15,5	NON AMMESSA (punteggio insufficiente curriculum)	---
FRANCESCO	FARRIS	6	14	20	AMMESSO	GEP, FOLLOWING TRKB STIMULATION OR NTRK2 KNOCK OUT, SHOWS DEREGULATION OF DIFFERENT CRUCIAL PATHWAY IN GLIOBLASTOMA
VANESSA KATIA	FAVASULI	8	13,5	21,5	AMMESSA	INVESTIGATING THE ROLE OF THE LNCRNA NEAT1 DEREGULATED IN MULTIPLE MYELOMA
BEATRICE	GATTO	7	12,5	19,5	AMMESSA	TOWARD PRECISION MEDICINE: SEARCHING FOR SEX BIOLOGICAL DIFFERENCES IN HUMAN ENDOTHELIAL CELLS
DOMENICA	GIANNANDREA	8	14	22	AMMESSA	The EV-mediated education of the Multiple Myeloma microenvironment: a focus on the jagged 1 and jagged 2 contribution.

7 settembre 2018, ore 9.00
LITA Segrate, Via Fratelli Cervi 93 – 20090 Segrate

LAURA	GUARNACCIA	8	17	25	AMMESSA	Investigation of exosome role in orchestrating tumor microenvironment and signalling to discover novel diagnostic and prognostic biomarkers and new promising therapeutic targets for glioblastoma therapy
ISTI HANIYATUN	KHASANAH	--	--	--	ESCLUSA (titolo di studio non idoneo)	---
FEDERICA	MANGILI	8	12	20	AMMESSA	Effects of filamin A (FLNA) phosphorylation on somatostatin receptor type 2 (SSTR2) and dopamine receptor 2 (DRD2): molecular mechanisms involved in signal transduction
SARA	MAZZOLENI	9	12,5	21,5	AMMESSA	Characterization of a new conditional PCDH19 KO mouse model to understand the pathophysiology of PCDH19 Female Epilepsy (PCDH19 – FE)
TASNEEM ELAMIN ELAWAD	MOHMMED	6	12,5	18,5	AMMESSA	Comparative analysis of the molecular and cell biology of hepatitis C virus- bat host interactions and hepatitis C virus- human host interaction
LETIZIA LUIGIA	MOLGORA	5	8,5	13,5	NON AMMESSA (punteggio insufficiente curriculum)	---
SARA	OTTOLENGHI	5	13	18	AMMESSA	Hyperoxia-induced damage in anesthesia: characterization and prevention
FEDERICA	PEREGO	8	14	22	AMMESSA	Chronic ulcers in the elderly: potential ability of dextran oxygen-loaded nanodroplets to restore a normoxia-like environment to improve wound healing
ALEX	PEZZOTTA	8	15	23	AMMESSO	Unravelling the role of Sox18 in the development of zebrafish lymphatic system
ALESSANDRO	PIGONI	4	19	23	NON AMMESSO (punteggio insufficiente progetto)	---

DAVIDE	SARONNI	8	13	21	AMMESSO	Zebrafish tumor xenograft: a preclinical tool to design new therapeutic strategies in neuroendocrine tumors
ROBERTA	SCRIMIERI	8	11	19	AMMESSA	Studies on endothelial function/dysfunction: Txnip as a novel biomarker for cardiovascular complications associated with diabetes
RAED	SELMI	4	10	14	NON AMMESSO (punteggio insufficiente progetto)	---
MARA CETTY	SPINELLA	7	15	22	AMMESSA	Sviluppo di tools di imaging per descrivere le dinamiche genomiche 3D di LINE-1 nell'artrite reumatoide
FRANCESCA	TUMIATTI	6	11	17	AMMESSA	Role of β polymerase in the cisplatin resistance in non-small cell lung cancer (NSCLC)
PIETRO	VERCESI	7	12,5	19,5	AMMESSO	Somatostatin receptor 5 (SST5) signal transduction in ACTH-secreting pituitary tumors: role for cytoskeleton proteins and somatic mutation of USP8 deubiquitinase
STEFANIA	ZORZIN	8	16	24	AMMESSA	Novel strategies for spinal cord injury repair

Per essere ammesso al colloquio il candidato deve ottenere nel curriculum minimo 10 punti e nel progetto di ricerca 5 punti;
In caso di esclusione indicare il motivo.

Milano, 9 Luglio 2018